Therapeutic targeting of PFKFB3 with a novel glycolytic inhibitor PFK158 promotes lipophagy and chemosensitivity in gynecologic cancers

Metabolic alterations are increasingly recognized as important novel anti‐cancer targets. Among several regulators of metabolic alterations, fructose 2,6 bisphosphate (F2,6BP) is a critical glycolytic regulator. Inhibition of the active form of PFKFB3(ser461) using a novel inhibitor, PFK158 resulted...

Descripción completa

Detalles Bibliográficos
Autores principales: Mondal, Susmita, Roy, Debarshi, Sarkar Bhattacharya, Sayantani, Jin, Ling, Jung, Deokbeom, Zhang, Song, Kalogera, Eleftheria, Staub, Julie, Wang, Yaxian, Xuyang, Wen, Khurana, Ashwani, Chien, Jeremey, Telang, Sucheta, Chesney, Jason, Tapolsky, Gilles, Petras, Dzeja, Shridhar, Viji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2018
Materias:
Cancer Therapy and Prevention
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6261695/
https://www.ncbi.nlm.nih.gov/pubmed/30226266
http://dx.doi.org/10.1002/ijc.31868

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6261695/
https://www.ncbi.nlm.nih.gov/pubmed/30226266
http://dx.doi.org/10.1002/ijc.31868

Ejemplares similares